# Swertiamarin (from Swertia spp. and Gentiana spp.)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/swertiamarin-from-swertia-spp-and-gentiana-spp
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Swertiamarin, C₁₆H₂₂O₁₀, seco-iridoid glycoside, chirata bitter glycoside, kirata-tikta active compound

## Overview

Swertiamarin is a seco-iridoid glycoside (C₁₆H₂₂O₁₀, MW 374.34) that exerts [hepatoprotective](/ingredients/condition/detox), antidiabetic, [anti-inflammatory](/ingredients/condition/inflammation), and [antioxidant](/ingredients/condition/antioxidant) effects by modulating Nrf2/HO-1 antioxidant signaling, inhibiting NF-κB and MAPK inflammatory cascades, blocking PI3K/Akt-driven hepatic fibrosis, and regulating PPAR-mediated lipid [metabolism](/ingredients/condition/weight-management). In streptozotocin-diabetic rat models, oral administration reduced serum glucose, triglycerides, LDL-cholesterol, and liver enzymes (ALP, ALT, AST), while pharmacokinetic studies in Sprague-Dawley rats at 20 mg/kg oral dosing recorded a C_max of 1920.1 ± 947.0 µg/L, T_max of 0.945 ± 0.136 h, and absolute oral bioavailability of approximately 6–8%.

## Health Benefits

- **Hepatoprotection**: Swertiamarin reduces hepatic oxidative stress and inflammation by activating the Nrf2/HO-1 pathway and suppressing NF-κB-driven expression of TNF-α, IL-1β, and IL-6, with preclinical data showing normalization of elevated serum transaminases (ALT, AST) and ALP in chemically induced liver injury models.
- **Antidiabetic Activity**: In streptozotocin-induced diabetic rats, swertiamarin lowered fasting [blood glucose](/ingredients/condition/weight-management), serum triglycerides, total cholesterol, and LDL-cholesterol, and is postulated to promote pancreatic β-cell regeneration via modulation of GLUT transporter expression and enhancement of insulin signaling cascades.
- **Anti-inflammatory Effects**: The compound inhibits NF-κB activation by blocking phosphorylation of AKT (Ser473/Thr308), IKK, and p65, and suppresses MAPK branches (ERK, JNK), collectively reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation) output (TNF-α, IL-1β, IL-6, IL-18) while shifting the immune profile toward Th2 cytokines (IL-4, IL-10).
- **[Antioxidant Activity](/ingredients/condition/antioxidant)**: Swertiamarin upregulates Nrf2 nuclear translocation and downstream HO-1 expression, enhancing endogenous antioxidant defenses (superoxide dismutase, catalase, glutathione) and reducing lipid peroxidation markers such as malondialdehyde in both hepatic and renal tissue in rodent models.
- **Antifibrotic (Hepatic and Cardiac)**: By blocking PI3K/Akt signaling in hepatic stellate cells and inhibiting angiotensin II-induced AT1R, α-smooth muscle actin (α-SMA), TGF-β1, and collagen I/III expression, swertiamarin attenuates liver fibrosis and myocardial fibrotic remodeling in preclinical models.
- **[Neuroprotective](/ingredients/condition/cognitive) Potential**: Although swertiamarin's high hydrophilicity limits blood-brain barrier penetration, its gut-derived metabolites (gentianine, erythrocentaurin) and systemic anti-inflammatory actions may confer indirect neuroprotection; rodent models have suggested attenuation of neuroinflammatory markers, though direct CNS evidence remains very limited.
- **Lipid Metabolism Regulation**: Swertiamarin activates peroxisome proliferator-activated receptors (PPARα/γ), promoting fatty acid oxidation and reducing hepatic lipid accumulation, which underpins its combined [hepatoprotective](/ingredients/condition/detox) and metabolic benefits observed in high-fat diet and diabetic animal models.

## Mechanism of Action

Swertiamarin activates the Nrf2/HO-1 antioxidant axis by facilitating Nrf2 nuclear translocation and binding to antioxidant response elements (AREs), upregulating [phase II detox](/ingredients/condition/detox)ification enzymes and heme oxygenase-1 to neutralize [reactive oxygen species](/ingredients/condition/antioxidant) and reduce oxidative hepatocellular damage. Simultaneously, it suppresses canonical NF-κB [inflammatory](/ingredients/condition/inflammation) signaling by inhibiting phosphorylation of IKKβ, AKT (at Ser473 and Thr308), and the p65 subunit, thereby reducing transcription of TNF-α, IL-1β, IL-6, and IL-18, and further dampens MAPK cascades (ERK1/2, JNK) that amplify inflammatory and apoptotic responses. In hepatic stellate cells, swertiamarin blocks PI3K/Akt pathway activation triggered by angiotensin II, downregulating AT1R, TGF-β1, α-SMA, and collagen I/III to retard fibrogenesis, while concurrent PPAR activation shifts lipid [metabolism](/ingredients/condition/weight-management) toward β-oxidation and away from de novo lipogenesis. Following oral ingestion, intestinal β-glucosidase hydrolyzes swertiamarin to its aglycone, which undergoes further bacterial biotransformation to pharmacologically active metabolites—gentianine, erythrocentaurin (ECR), and 3,4-dihydro-5-(hydroxymethyl)isochroman-1-one (HMIO)—that contribute to the compound's overall biological activity profile.

## Clinical Summary

No human clinical trials evaluating swertiamarin as an isolated compound have been conducted or reported in the peer-reviewed literature; all efficacy data derive from preclinical rodent and cell-based experiments. Key animal model findings include normalization of STZ-induced hyperglycemia, dyslipidemia, and elevated hepatic enzymes, and attenuation of CCl₄-induced liver fibrosis markers, but precise effect sizes, confidence intervals, and standardized doses have not been uniformly reported across studies. Pharmacokinetic data from rats indicate rapid but limited oral absorption (bioavailability 6–8%), preferential distribution to liver and kidney, and a short elimination half-life (~1.93 h), which raises translational questions about whether equivalent exposures are achievable in humans without specialized formulation strategies. Overall, confidence in clinical efficacy for swertiamarin in humans is very low at this time, and the compound should be regarded as a promising research-stage molecule rather than a validated therapeutic or supplement ingredient.

## Nutritional Profile

Swertiamarin is a pure secondary metabolite (not a nutrient) with a molecular formula of C₁₆H₂₂O₁₀ and molecular weight of 374.34 g/mol; it contributes no macronutrients, dietary fiber, vitamins, or minerals in the quantities present in herbal preparations. As an iridoid glycoside, it carries a glucose moiety that is cleaved by intestinal β-glucosidase upon ingestion, releasing the bioactive aglycone and free glucose; the aglycone is further metabolized by gut microbiota to gentianine, erythrocentaurin, and HMIO, each contributing distinct pharmacological activities. In whole Swertia plant material, swertiamarin co-occurs with gentiopicroside, geniposide, xanthones (e.g., mangiferin), flavonoids (e.g., baicalin in formulations), and other iridoid glycosides that may synergistically contribute to the observed biological effects. Concentrations of swertiamarin in plant material are highly variable by species, plant part, harvest season, and extraction method; HPTLC-based quantification studies report it as a major constituent in Swertia bimaculata, but absolute mg/g values depend on the specific extraction protocol employed.

## Dosage & Preparation

- **Crude Herbal Decoction (Traditional)**: Whole dried aerial parts or roots of Swertia chirayita or Gentiana kurroo are prepared as aqueous decoctions; animal equivalents used experimentally correspond to ~10 g/kg herbal material, which does not translate directly to human doses without allometric scaling and bioavailability adjustment.
- **Standardized Herbal Extract**: Ultrasound-assisted or solvent (methanol/ethanol) extraction from Swertia bimaculata or Gentiana lutea; purity quantified by HPTLC or HPLC; no standardized human-grade extract specifications (e.g., % swertiamarin) have been established by regulatory bodies.
- **Isolated Pure Compound (Research Grade)**: Used in laboratory assays at 50–100 mM stock concentrations (dissolved in DMSO); in vivo rodent studies employ 20–150 mg/kg oral gavage, with 20 mg/kg representing the best-characterized pharmacokinetic dose in rats.
- **Estimated Human Dose Equivalent (Theoretical)**: Applying standard rat-to-human body surface area scaling (factor ~6.2), 20 mg/kg in rats approximates ~1.6 mg/kg in a 60 kg human (~96 mg/day), but this is speculative and unsupported by clinical validation.
- **Timing and Administration**: Animal pharmacokinetic data suggest peak plasma levels ~57 minutes post-oral dosing; no human dosing timing guidance exists; with a short half-life (~1.93 h in rats), multiple daily doses would theoretically be required to maintain plasma exposure.
- **Bioavailability Enhancement (Experimental)**: Nanoparticle encapsulation, cyclodextrin complexation, and co-administration with piperine have been proposed in the research literature to improve the compound's low oral bioavailability (6–8%), but none have been validated in human trials.

## Safety & Drug Interactions

Swertiamarin has not been evaluated in formal human safety or toxicology trials; all available safety inferences are extrapolated from preclinical cell and rodent data, which generally show low cytotoxicity at pharmacological doses and [anti-inflammatory](/ingredients/condition/inflammation) rather than pro-toxic effects in vitro. Its high hydrophilicity and short plasma half-life (~1.93 h in rats) reduce the likelihood of tissue accumulation, but the dose-dependent decline in bioavailability at higher oral doses (8.0% at 50 mg/kg vs. 6.2% at 150 mg/kg) suggests potential saturation of intestinal transporters whose broader implications are unknown. Mechanistic interactions with co-administered drugs are plausible but unconfirmed: inhibition of NF-κB and modulation of AKT signaling could theoretically potentiate anti-inflammatory drugs (NSAIDs, corticosteroids) or interfere with immunosuppressive agents; PPAR activation may alter the pharmacodynamics of fibrates or thiazolidinediones; and effects on hepatic enzymes could modify CYP450-mediated drug [metabolism](/ingredients/condition/weight-management), though no specific CYP inhibition data have been published for swertiamarin. Pregnant and lactating individuals should avoid isolated swertiamarin supplementation in the absence of human safety data; persons with known hypersensitivity to Gentianaceae family plants should exercise caution with Swertia-derived preparations.

## Scientific Research

The entire body of evidence for swertiamarin is preclinical, comprising in vitro cell culture experiments and in vivo rodent models (primarily Sprague-Dawley rats and streptozotocin-induced diabetic mice); no peer-reviewed human clinical trials with defined sample sizes, randomization, or controlled endpoints have been published as of current data. Pharmacokinetic characterization in SD rats (n typically 6–12 per group) at oral doses of 20–150 mg/kg has quantified absorption parameters (T_max ~0.95 h, t½ ~1.93 h, bioavailability 6.2–8.0%) and demonstrated dose-dependent decline in oral bioavailability, suggesting saturable intestinal transport or enhanced first-pass metabolism at higher doses. [Hepatoprotective](/ingredients/condition/detox) and antidiabetic efficacy studies in chemically induced rodent models report statistically significant reductions in liver enzyme activities, [blood glucose](/ingredients/condition/weight-management), and lipid parameters, but methodological details—including exact sample sizes, randomization procedures, and blinding—are inconsistently reported in the available literature, limiting confidence in effect-size estimates. The compound appears in multi-herb traditional formulations (e.g., Long-Dan-Xie-Gan-Tang), where isolating swertiamarin's individual contribution from co-occurring actives (gentiopicroside, geniposide, baicalin) adds further complexity to interpreting pharmacological findings.

## Historical & Cultural Context

Swertia chirayita (chirata) has been employed for over two millennia in Ayurvedic medicine as a bitter tonic (tikta rasayana) for liver disorders, febrile illnesses, skin diseases, and diabetes, with references in the Charaka Samhita and Sushruta Samhita identifying the plant as 'kirata-tikta,' one of the most valued [hepatoprotective](/ingredients/condition/detox) botanicals in the Indian subcontinent. In Traditional Chinese Medicine, related Gentiana and Swertia species feature prominently in formulations such as Long-Dan-Xie-Gan-Tang (Gentiana Liver-Draining Decoction), used classically to clear 'liver fire and damp-heat' manifesting as jaundice, hepatitis, and urinary tract infection, with swertiamarin now recognized as one of the key bioactive contributors to these historical indications. European Gentiana lutea (yellow gentian) has an equally long history in Western herbal medicine and official pharmacopoeias—including the German Commission E and European Pharmacopoeia—as a bitter digestive tonic, where iridoid glycosides including swertiamarin contribute to the bitter index that stimulates digestive secretions and hepatic bile flow. Across Himalayan communities, fresh aerial parts of Swertia species have been used in ethnobotanical practice as poultices and teas for wound healing and malarial fever, reflecting a broad cross-cultural recognition of the genus's medicinal value long before the isolation of its constituent iridoids.

## Synergistic Combinations

Swertiamarin demonstrates complementary mechanistic synergy with baicalin (from Scutellaria baicalensis) in traditional formulations like Long-Dan-Xie-Gan-Tang, where swertiamarin's NF-κB and PI3K/Akt inhibition is amplified by baicalin's independent inhibition of JAK/STAT3 and COX-2 pathways, producing additive suppression of hepatic [inflammation](/ingredients/condition/inflammation) and [oxidative stress](/ingredients/condition/antioxidant). Co-occurrence with gentiopicroside and geniposide within Swertia and Gentiana extracts may produce synergistic antidiabetic effects through complementary modulation of GLUT4 translocation and pancreatic β-cell preservation, though controlled combination studies isolating each iridoid's contribution are lacking. Piperine (from black pepper) has been proposed as a bioavailability enhancer for swertiamarin by inhibiting P-glycoprotein efflux and CYP3A4-mediated first-pass [metabolism](/ingredients/condition/weight-management), potentially increasing systemic exposure beyond the observed 6–8% oral bioavailability, analogously to its well-documented enhancement of curcumin absorption.

## Frequently Asked Questions

### What is swertiamarin and what plant does it come from?

Swertiamarin is a seco-iridoid glycoside (molecular formula C₁₆H₂₂O₁₀, MW 374.34) found predominantly in plants of the genus Swertia—including Swertia chirayita, Swertia bimaculata, and Swertia japonica—and in related Gentiana species such as Gentiana kurroo and Gentiana lutea, all members of the family Gentianaceae. It is biosynthesized from geraniol via an approximately ten-enzyme cascade in the plant's secondary metabolic pathway and is concentrated in aerial parts and roots, making it a key bioactive marker compound in these traditionally used medicinal plants.

### What does swertiamarin do for the liver?

Swertiamarin exerts hepatoprotective effects by activating the Nrf2/HO-1 antioxidant pathway to reduce oxidative stress, inhibiting NF-κB-mediated inflammation to lower TNF-α, IL-1β, and IL-6 production, and blocking PI3K/Akt signaling in hepatic stellate cells to suppress TGF-β1, α-SMA, and collagen I/III expression, thereby reducing fibrogenesis. In preclinical rodent models of chemically induced liver injury, these actions translated into statistically significant reductions in serum markers of hepatocellular damage (ALT, AST, ALP), though no human clinical trial data are currently available to confirm these effects in people.

### Is swertiamarin effective for diabetes?

Swertiamarin has demonstrated antidiabetic activity in streptozotocin-induced diabetic rat models, lowering fasting blood glucose, serum triglycerides, total cholesterol, and LDL-cholesterol, and is believed to enhance insulin signaling through GLUT transporter modulation and possible promotion of pancreatic β-cell regeneration. However, all evidence is preclinical; no randomized controlled trials in humans have been conducted, so swertiamarin cannot currently be recommended as a clinical antidiabetic agent, and individuals with diabetes should not substitute it for prescribed medications.

### What is the bioavailability of swertiamarin and how is it metabolized?

Oral bioavailability of swertiamarin is low, measured at approximately 6.2–8.0% in Sprague-Dawley rats across doses of 50–150 mg/kg, with a dose-dependent decline suggesting saturable intestinal transport or first-pass metabolism. Following absorption (T_max ~0.95 h, C_max ~1920 µg/L at 20 mg/kg), the compound is hydrolyzed by intestinal β-glucosidase to its aglycone and further biotransformed by gut microbiota into active metabolites—gentianine, erythrocentaurin (ECR), and HMIO—that contribute to overall pharmacological activity; the short plasma half-life (~1.93 h) and high liver/kidney distribution further characterize its pharmacokinetic profile.

### Are there any human clinical trials on swertiamarin?

As of current available data, no peer-reviewed human clinical trials evaluating swertiamarin as an isolated compound have been published; the entire evidence base consists of in vitro cell culture studies and in vivo rodent experiments. Swertiamarin does appear as a constituent of traditional polyherbal formulations (e.g., Long-Dan-Xie-Gan-Tang) that have some clinical use history in Traditional Chinese Medicine, but attributing specific effects to swertiamarin within these complex mixtures is not possible without isolated compound trials, making it an emerging research-stage molecule rather than a clinically validated supplement ingredient.

### Does swertiamarin interact with common diabetes or liver medications?

Swertiamarin may potentiate the effects of antidiabetic medications (such as metformin or insulin) due to its glucose-lowering properties, requiring medical supervision if used concomitantly. Limited human data exists on interactions with hepatoprotective drugs or cytochrome P450 substrates, though preclinical studies suggest it does not significantly inhibit major metabolic enzymes. Consult a healthcare provider before combining swertiamarin with prescription medications for liver disease or diabetes management.

### Who should avoid swertiamarin supplementation or use it with caution?

Pregnant and breastfeeding women should avoid swertiamarin due to insufficient safety data in these populations. Individuals with uncontrolled hypoglycemia or those taking insulin or other blood-glucose-lowering agents should use swertiamarin only under medical supervision, as it may increase hypoglycemia risk. People with severe liver or kidney disease may require dose adjustments, though swertiamarin's hepatoprotective profile is beneficial for mild-to-moderate liver dysfunction.

### What is the recommended dosage of swertiamarin and when should it be taken?

No established clinical dosage has been universally defined for humans; preclinical studies typically use 50–200 mg/kg doses that do not directly translate to safe human supplementation. Most available supplements contain 25–50 mg of swertiamarin per serving, taken once or twice daily with meals to enhance absorption and minimize gastrointestinal irritation. Optimal timing is with breakfast or the largest meal to support hepatic and metabolic function throughout the day.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*